Launched in the United Kingdom in 2008, Xeomin is the third botulinum toxin type
A to be promoted in the United Kingdom. Xeomin is manufactured by a
German manufacturer - Mers Pharmaceuticals and has just been approved for use
in the United States.
The average first onset of action or effect is seen within four days after
injection. The effect of each treatment generally lasts approximately 3-4
months; however, it may last significantly longer or shorter.
Shelf Life of Xeomin
Chemical and physical in-use stability has been
demonstrated for 24 hours at 2 to 8°C. Technically, the product should be
used immediately for best results.